Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Harbin Medical University, 143 Yiman Street, Nangang District, Harbin, Heilongjiang Province, People's Republic of China, 150001.
Cell Mol Biol (Noisy-le-grand). 2022 Feb 4;67(5):233-239. doi: 10.14715/cmb/2021.67.5.32.
Oral squamous cell carcinoma (OSCC) is one of the ten most common malignant tumors globally. This study aimed to evaluate the expression changes of Cytokeratin 19 (CK19), vascular endothelial growth factor (VEGF), P53, ki67, and c-ert-B2 in OSCC patients. For this purpose, 30 patients were selected as the case group and 30 healthy individuals as the control group. The expression of CK19 and VEGF genes in their blood serum was measured. Also, the expression of ki67, P53, and c-ert-B2 markers in squamous cell carcinoma was evaluated using immunohistochemistry. T-test was used to analyze the data. The results showed that the presence of CK19 marker in people with OSCC was positive in 17 out of 30 patients and VEGF marker in 23 out of 30 patients. The mean of ki67 positive, P53 positive, and Cerb-B2 positive cells were 399.4, 221.4, and 26.8, respectively. The correlation test between the indices showed a statistical correlation between the incidence of ki67 and P53 (r = 91.5% and p = 0.02). While statistical correlation was not seen between the incidence of ki67 and Cerb-B2 index (r = -1.7% and p = 0.97) and P53 and C-erb-B2 index (r = -13% and p = 0.8) (p <0.05). In general, the expression of VEGF and CK19 genes is higher in patients with OSCC than in healthy individuals. Therefore, examining the expression level of these two biomarkers in the blood of OSCC patients can be considered as a diagnostic screening method in the early stages of the disease. The immunohistochemical study of squamous cell carcinoma can also be used as a diagnostic screening test in the early stages of the disease.
口腔鳞状细胞癌（OSCC）是全球十大最常见恶性肿瘤之一。本研究旨在评估细胞角蛋白 19（CK19）、血管内皮生长因子（VEGF）、P53、ki67 和 c-ert-B2 在 OSCC 患者中的表达变化。为此，选择 30 名患者作为病例组，30 名健康个体作为对照组。测量他们血清中 CK19 和 VEGF 基因的表达。此外，还通过免疫组织化学评估鳞状细胞癌中 ki67、P53 和 c-ert-B2 标志物的表达。使用 T 检验分析数据。结果表明，30 例 OSCC 患者中有 17 例 CK19 标志物阳性，23 例 VEGF 标志物阳性。ki67 阳性、P53 阳性和 Cerb-B2 阳性细胞的平均值分别为 399.4、221.4 和 26.8。各指标之间的相关性检验表明，ki67 与 P53 的发生率呈统计学相关性（r=91.5%，p=0.02）。然而，ki67 与 Cerb-B2 指数（r=-1.7%，p=0.97）和 P53 与 C-erb-B2 指数（r=-13%，p=0.8）之间未观察到统计学相关性（p<0.05）。一般来说，OSCC 患者中 VEGF 和 CK19 基因的表达高于健康个体。因此，检测 OSCC 患者血液中这两种生物标志物的表达水平可以作为疾病早期的诊断筛选方法。鳞状细胞癌的免疫组织化学研究也可以作为疾病早期的诊断筛选试验。
